A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena

Experimental Neurology

Volumn 194, Issue 2, 2005, Pages 355-362

  Solbrig, Marylou V ^a,b   Adrian, Russell ^a   Baratta, Janie ^a   Piomelli, Daniele ^b   Giuffrida, Andrea ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Anandamide; Basal ganglia; Borna; Rat; Seizure

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; LEVODOPA; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NALOXONE; OPIATE ANTAGONIST; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BORNA DISEASE VIRUS; CONTROLLED STUDY; CONVULSION; DRUG EFFECT; DYSKINESIA; ELECTROENCEPHALOGRAPHY; EXTRAPYRAMIDAL SYSTEM; HIPPOCAMPUS; LIMBIC CORTEX; MALE; MUSCLE TONE; MYOCLONUS; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; SUBTHALAMIC NUCLEUS; VIRUS INFECTION;

ANIMALS; ANTICONVULSANTS; ARACHIDONIC ACIDS; BASAL GANGLIA; BORNA DISEASE; CONVULSANTS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; LIMBIC SYSTEM; MALE; MOVEMENT DISORDERS; NALOXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, INBRED LEW; RECEPTOR, CANNABINOID, CB1; SEIZURES;

EID: 22044455129     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2005.02.017     Document Type: Article

References (43)

1. J.C.M. Brust Neurological Aspects of Substance Abuse 1993 Butterworth-Heinemann Stoneham, MA
2. D.P. Crockett, S. Maslany, S.L. Harris, and M.D. Egger Enhanced cytochrome-oxidase staining of the cuneate nucleus in the rat reveals a modifiable somatotopic map Brain Res. 612 1993 41 55
3. T. Curran, M.B. Gordon, K.L. Rubino, and L.C. Sambucetti Isolation and characterization of the c-fos (rat) cDNA and analysis of post-translational modification in vitro Oncogene 2 1987 79 84
4. J. Engel Jr., and L.L. Rocha Interictal behavior disturbances: a search for molecular substrates Epilepsy Res., Suppl. 9 1992 341 349
5. M. Filion Physiologic basis of dyskinesia Ann. Neurol. 47 Suppl. 1 2000 S35 S41
6. T.F. Freund, and G. Buzsaki Interneurons of the hippocampus Hippocampus 6 1996 347 470
7. T.F. Freund, I. Katona, and D. Piomelli Role of endogenous cannabinoids in synaptic signaling Physiol. Rev. 83 2003 1017 1066
8. A. Giuffrida, F. Rodriguez de Fonseca, and D. Piomelli Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry Anal. Biochem. 280 2000 87 93
9. A. Giuffrida, F. Rodriguez de Fonseca, F. Nava, P. Loubet-Lescoulie, and D. Piomelli Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404 Eur. J. Pharmacol. 408 2000 161 168
10. A. Giuffrida, F.M. Leweke, C.W. Gerth, D. Schreiber, D. Koethe, J. Faulhaber, J. Klosterkotter, and D. Piomelli Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms Neuropsychopharmacology 29 2004 2108 2114
11. D.W. Gross, J. Hamm, N.L. Ashworth, and D. Quigley Marijuana use and epilepsy Neurology 62 2004 2095 2097
12. B. Hine, E. Friedman, M. Torrelio, and S. Gershon Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol Science 187 1975 443 445
13. K. Ikuta, M.S. Ibrahim, T. Kobayashi, and K. Tomonaga Borna disease virus and infection in humans Front. Biosci. 7d 2002 470 495
14. J.C. Jerman, S.J. Brough, J.B. Davis, D.N. Middlemiss, and D. Smart The anandamide transport inhibitor AM404 is an agonist at the rat vanilloid receptor (VR1) Br. J. Pharmacol. 129 2000 73
15. R. Karler, W. Cely, and S.A. Turkanis The anticonvulsant activity of cannabidiol and cannabinol Life Sci. 13 1973 1527 1531
16. R. Karler, W. Cely, and S.A. Turkanis Anticonvulsant properties of delta-9-tetrahydrocannabinol and other cannabinoids Life Sci. 15 1974 931 947
17. I. Katona, B. Sperlagh, A. Sik, A. Kafalvi, K. Mackie, and T.F. Freund Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons J. Neurosci. 19 1999 4544 4558
18. H. Kita, H.T. Chang, and S.T. Kitai Pallidal inputs to subthalamus: intracellular analysis Brain Res. 264 1983 255 265
19. S.T. Kitai, and J.M. Deniau Cortical inputs to the subthalamus: intracellular analysis Brain Res. 214 1981 411 415
20. S. Kullback Information Theory and Statistics 1968 Dover New York
21. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, F. Beslot, G.A. Bohme, A. Imperato, T. Pedrazzini, B.P. Roques, G. Vassart, W. Fratta, and M. Parmentier Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
22. P. Mailleux, and J.J. Vanderhaeghen Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding autoradiography and in situ hybridization histochemistry Neuroscience 48 1992 655 668
23. J. Manzanares, J. Corchero, J. Romero, J.J. Fernando-Ruiz, J.A. Ramos, and J.A. Fuentes Pharmacological and biochemical interactions between opioids and cannabinoids Trends Pharmacol. Sci. 20 1999 287 294
24. A.S. Miller, M.C. Sañudo-Peña, and J.M. Walker Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus Brain Res. 793 1998 7 11
25. Y. Nakamura, H. Takahasi, Y. Shoya, T. Nakaya, M. Watanabe, K. Tomonaga, K. Iwahashi, K. Ameno, N. Momiyama, H. Taniyama, T. Sata, T. Kurata, J.C. de la Torre, and K. Ikuta Isolation of Borna disease virus from human brain tissue J. Virol. 74 2000 4601 4611
26. M. Navarro, M.R.A. Carrere, W. Fratta, O. Valverde, G. Cossu, L. Fattore, J.A. Chowen, R. Gomez, I. del Arco, M.A. Villanua, R. Maldonado, G.F. Koob, and F. Rodriguez de Fonseca Functional interaction between opioid and cannabinoid receptors in drug self-administration J. Neurosci. 21 2001 5344 5350
27. J.A. Obeso, M.C. Rodriguez-Oroz, M. Rodruguez, M.E. DeLong, and C.W. Olanow Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model Ann. Neurol. 47 Suppl. 1 2000 S22 S34
28. R.H.P. Porter, J.G. Greene, D.S. Higgins, and J.T. Greenamyre Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion J. Neurosci. 14 1994 7192 7199
29. R.J. Racine Modification of seizure activity by electrical stimulation. II. Motor seizure Electroencephalogr. Clin. Neurophysiol. 32 1972 281 294
30. M. Simonato, and P. Romualdi Dynorphin and epilepsy Prog. Neurobiol. 50 1996 557 583
31. M.V. Solbrig, and G.F. Koob Epilepsy, CNS viral injury and dynorphin Trends Pharmacol. Sci. 25 2004 98 104
32. M.V. Solbrig, G.F. Koob, J.F. Fallon, and W.I. Lipkin Tardive dyskinetic syndrome in rats infected with Borna disease virus Neurobiol. Dis. 1 1994 111 119
33. M.V. Solbrig, G.F. Koob, and W.I. Lipkin Naloxone-induced seizures in rats infected with Borna disease virus Neurology 46 1996 1170 1171
34. M.V. Solbrig, G.F. Koob, and W.I. Lipkin Cocaine sensitivity in Borna disease virus infected rats Pharmacol. Biochem. Behav. 59 1998 1047 1052
35. B. Szabo, L. Dörner, C. Pfreundtner, W. Nörenberg, and K. Starke Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum Neuroscience 85 1998 395 403
36. F.C. Tortella Endogenous opioid peptides and epilepsy: quieting the seizing brain? Trends Pharmacol. Sci. 9 1988 366 372
37. M. Vila, R. Levy, M.-T. Herrero, B. Faucheux, J.A. Obeso, Y. Agid, and E.C. Hirsch Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study Neuroscience 71 1996 903 912
38. J.L. Vitek, and M. Giroux Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia Ann. Neurol. 47 Suppl. 1 2000 S131 S140
39. M.J. Wallace, B.R. Martin, and R.J. DeLorenzo Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity Eur. J. Pharmacol. 452 2002 295 301
40. M.J. Wallace, R.E. Blair, K.W. Falenski, B.R. Martin, and R.J. DeLorenzo The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy J. Pharmacol. Exp. Ther. 307 2003 129 137
41. I. Wallmichrath, and B. Szabo Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse Neuroscience 113 2002 671 682
42. S.P. Welch, and D.L. Stevens Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice J. Pharmacol. Exp. Ther. 262 1992 10 16
43. R.I. Wilson, and R.A. Nicoll Endocannabinoid signaling in the brain Science 296 2002 678 682